Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabotegravir - ViiV Healthcare

Next Previous
Drug Profile

Cabotegravir - ViiV Healthcare

Alternative Names: 1265744; 744 LA Injection; APRETUDE; Apretude; CAB LA - ViiV Healthcare; Cabotegravir long acting; Cabotegravir sodium; GSK-1265744; GSK-1265744A; GSK-1265744B; GSK-744; GSK-744-LA; GSK1265744 LAP; S-265744; S-265744B; S/GSK-1265744; S/GSK1265744 LAP

Latest Information Update: 24 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi - GlaxoSmithKline (JV)
  • Developer Gilead Sciences; National Institute of Allergy and Infectious Diseases; ViiV Healthcare
  • Class Amides; Antiretrovirals; Fluorobenzenes; Oxazoles; Pyrazines; Pyridones; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV infections
  • Registered HIV-1 infections

Most Recent Events

  • 23 Jun 2026 ViiV Healthcare plans a phase III trial for HIV Infections (Prevention, Combination therapy, Treatment experienced) in June 2026 (NCT07650916)
  • 15 Apr 2026 Phase-I/II clinical trials in HIV infections (In neonates, Prevention) in South Africa (IM) (NCT07275606)
  • 10 Dec 2025 ViiV Healthcare plans a phase I/II CABNATE trial for HIV Infections (In neonates) (PO, IM) in March 2026(NCT07275606 )

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top